First Patient Dosed in Stem Cell Trial for Graft-versus-host Disease – Bioscience Technology
Bioscience Technology |
First Patient Dosed in Stem Cell Trial for Graft-versus-host Disease
Bioscience Technology Australia-based regenerative medicine and stem cell company Cynata Therapeutics Ltd., announced that the first patient has been dosed with the company’s mesenchymal stem cell (MSC) therapy in a Phase 1 trial for steroid-resistant acute graft-versus … |
Local 8 Now |
Military school cadet gives stem cells to save a life
Local 8 Now Because at lacrosse camp his freshman year, he signed up with the HEADstrong foundation as a stem cell donor. And then: “I was in math class, and I thought something was wrong back home or something, because usually I don’t get phone call during class … |
|
Using CRISPR gene editing to slow cancer growth
FierceBiotech The gene editing technology CRISPR/CAS9 is being used to develop a host of new treatments, mostly for genetic diseases. But a team of researchers from the University of Rochester’s Center for RNA Biology are investigating whether gene editing can be … |
Madison.com |
I Still Can’t Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug
Madison.com JCAR015 was Juno’s lead CAR–T cell therapy, a relatively new type of cancer treatment in which patient’s T-cells are taken out of a patient’s body, treated so that they’re trained to attack the cancer cells expressing a specific protein, and then put … Vetr Inc. Upgrades Juno Therapeutics Inc (JUNO) to BuyThe Cerbat Gem Juno Therapeutics (JUNO) Getting Somewhat Favorable Press …Sports Perspectives |
|
CAR–T Cells from Creative Biolabs Help in the Treatment of Advanced Malignant Lymphoma
Digital Journal Recently, a hospital used the world’s most advanced cell immunotherapy (CAR–T) treatment to treat a patient with advanced malignant lymphoma. Two months after transfusion, most of the patient’s body mass disappeared, and relevant indicators returned to … |
Motley Fool |
I Still Can’t Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug
Motley Fool JCAR015 was Juno’s lead CAR–T cell therapy, a relatively new type of cancer treatment in which patient’s T-cells are taken out of a patient’s body, treated so that they’re trained to attack the cancer cells expressing a specific protein, and then put … |